Corcept Therapeutics (NASDAQ:CORT) Insider Roberto Wandenkolk Vieira Sells 296 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Roberto Vieira sold 296 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $100.82, for a total value of $29,842.72. Following the sale, the insider directly owned 3,946 shares in the company, valued at approximately $397,835.72. This represents a 6.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Roberto Wandenkolk Vieira also recently made the following trade(s):

• On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08.

Corcept Therapeutics Price Performance

CORT stock opened at $110.29 on Friday. The firm has a market cap of $11.92 billion, a price-to-earnings ratio of 262.60 and a beta of 0.45. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $126.38. The firm has a fifty day moving average price of $108.56 and a two-hundred day moving average price of $75.21.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. During the same period last year, the firm posted $0.29 EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. As a group, analysts expect that Corcept Therapeutics Incorporated will post 1.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Corcept Therapeutics

Several large investors have recently made changes to their positions in CORT. BlackRock Inc. bought a new position in Corcept Therapeutics in the 2nd quarter valued at about $1,080,964,000. First Trust Advisors LP lifted its stake in shares of Corcept Therapeutics by 213.5% in the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after acquiring an additional 1,480,059 shares during the period. Geode Capital Management LLC lifted its stake in shares of Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after acquiring an additional 734,646 shares during the period. Norges Bank bought a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $24,213,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $49,185,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CORT. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. HC Wainwright restated a “buy” rating and set a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday. Canaccord Genuity Group upped their price objective on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings lowered Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $138.17.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.